Journal of the neurological sciences · 2012
Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: an open label randomized trial.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khurana Navdeep, Garg Ravindra Kumar, Verma Rajesh, Malhotra Hardeep Singh, Singh Maneesh Kumar, Shukla Rakesh
Аннотация
BACKGROUND: Albendazole therapy has been found effective in solitary cysticercus granuloma. An optimal duration of albendazole therapy is not exactly known. Even 3-day therapy has been found effective.
METHODS: We included 105 patients of new-onset seizures and solitary cysticercus granuloma. We compared 3-day albendazole therapy and 15-day therapy with a control group. Each group had 35 patients. This was an open-label randomized trial. Patients were followed for 6 months. MRI was done after 6 months. Seizure recurrences during follow-up were noted.
RESULTS: After 6 months, albendazole group, in comparison to placebo group, had significantly higher proportion (43/70 versus 13/35) of patients in whom lesion had disappeared. Albendazole treatment for 15 days was insignificantly better in comparison to 3-day treatment regimen. In 15-day albendazole group lesser number of lesions (2.8%) was calcified than 3-day albendazole group (8.57%) or no treatment group (20%). After 6 months of follow-up, seizure recurrence was seen in 20 (19%) patients. The majority (15/20) of patients, experiencing seizure recurrence, had an abnormal follow-up MRI. Five patients had seizures despite normal MRI.
CONCLUSION: In conclusion, albendazole was significantly better in producing lesion resolution. A 15-day treatment with albendazole was better than 3-day treatment. Albendazole, possibly, led to less number of lesions got calcified and possibly, there was less risk of seizure recurrence.
METHODS: We included 105 patients of new-onset seizures and solitary cysticercus granuloma. We compared 3-day albendazole therapy and 15-day therapy with a control group. Each group had 35 patients. This was an open-label randomized trial. Patients were followed for 6 months. MRI was done after 6 months. Seizure recurrences during follow-up were noted.
RESULTS: After 6 months, albendazole group, in comparison to placebo group, had significantly higher proportion (43/70 versus 13/35) of patients in whom lesion had disappeared. Albendazole treatment for 15 days was insignificantly better in comparison to 3-day treatment regimen. In 15-day albendazole group lesser number of lesions (2.8%) was calcified than 3-day albendazole group (8.57%) or no treatment group (20%). After 6 months of follow-up, seizure recurrence was seen in 20 (19%) patients. The majority (15/20) of patients, experiencing seizure recurrence, had an abnormal follow-up MRI. Five patients had seizures despite normal MRI.
CONCLUSION: In conclusion, albendazole was significantly better in producing lesion resolution. A 15-day treatment with albendazole was better than 3-day treatment. Albendazole, possibly, led to less number of lesions got calcified and possibly, there was less risk of seizure recurrence.